Anti-vascular endothelial growth factor (anti-VEGF) therapy has transformed the management of retinal diseases, such as neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and retinal vein occlusion (RVO) over the past two decades. By inhibiting pathological neovascularisation and reducing vascular permeability, anti-VEGF injections have preserved vision for millions of patients worldwide. However, the need for frequent intravitreal injections remains a significant burden for patients and healthcare systems.
Sign up to keep reading
Create a free Member account at NZ Optics to read this article and more.
- Read all Member articles
- Full digital magazine archive
- Early access to new articles
